Plaur Antibody

What is PLAUR and why are PLAUR antibodies important in research?

PLAUR (plasminogen activator, urokinase receptor), also known as CD87, uPAR, U-PAR, and URKR, is a 37 kilodalton cell surface glycoprotein that plays crucial roles in diverse biological processes including cell migration, adhesion, and extracellular matrix degradation . The protein functions as a receptor for urokinase plasminogen activator (uPA), forming a system that regulates proteolytic cascades at the cell surface. PLAUR antibodies serve as indispensable tools for investigating this protein's expression, localization, and function across various experimental systems.

The importance of PLAUR antibodies in research stems from the protein's involvement in multiple pathophysiological processes. In HIV-1 pathogenesis, PLAUR functions as an antiviral factor in macrophages and dendritic cells (DCs) by restricting viral release from the cell membrane . In cancer biology, PLAUR is overexpressed in aggressive breast cancer subtypes, making it a potential diagnostic and therapeutic target . The ability to reliably detect and target PLAUR across these diverse research contexts makes PLAUR antibodies valuable tools for advancing our understanding of fundamental biological processes and disease mechanisms.

What are the common applications of PLAUR antibodies in laboratory settings?

PLAUR antibodies are utilized across a wide spectrum of laboratory techniques, each requiring specific consideration of antibody characteristics and experimental design. These applications span from protein detection to functional analysis and in vivo imaging.

When selecting antibodies for these applications, researchers should consider epitope location, since PLAUR is primarily localized at the cell membrane. For applications involving intact cells, antibodies targeting extracellular domains will provide optimal detection . Additionally, validation of antibody specificity for the intended application is crucial for obtaining reliable results.

How should researchers select the appropriate PLAUR antibody for specific experimental applications?

Selecting the optimal PLAUR antibody requires systematic consideration of multiple factors to ensure experimental success. Researchers should evaluate antibody characteristics in relation to their specific research objectives and experimental systems.

First, consider the intended application carefully. Different techniques require antibodies with distinct properties - for example, antibodies that work well in Western blotting may not be optimal for immunohistochemistry due to differences in protein conformation . Review manufacturer validation data for your specific application before purchase.

Second, evaluate the target specificity requirements. If studying specific PLAUR domains or isoforms, select antibodies targeting the relevant epitopes. N-terminal specific antibodies are available for researchers interested in particular domains of the protein . Cross-reactivity with related proteins or PLAUR from different species should be considered when working with non-human models.

Third, assess clonality requirements based on experimental needs. Monoclonal antibodies offer high specificity for a single epitope but may be more susceptible to epitope masking, while polyclonal antibodies recognize multiple epitopes but may show batch variation . For quantitative studies requiring high reproducibility, monoclonal or recombinant antibodies are preferable.

Fourth, verify species reactivity matches your experimental model. Available PLAUR antibodies have been validated for various species including human and mouse . When working with less common model organisms, thorough validation is essential before proceeding with major experiments.

Finally, consider the format requirements. Unconjugated antibodies offer flexibility for different detection systems, while directly conjugated antibodies (with biotin, fluorophores, or enzymes) simplify protocols but provide less amplification . For sandwich assays like ELISA, compatible antibody pairs recognizing different epitopes are necessary.

What are the best practices for validating PLAUR antibodies before experimental use?

Thorough validation of PLAUR antibodies is essential for generating reliable and reproducible experimental results. A comprehensive validation strategy should include multiple complementary approaches.

Begin with genetic validation using positive and negative controls. Test antibody reactivity in cell lines with confirmed PLAUR expression, alongside PLAUR-knockout or knockdown models . This verification step can identify potential cross-reactivity issues and confirm specificity for the target protein. Overexpression systems can serve as positive controls, particularly when studying cell types with naturally low PLAUR expression.

Perform biochemical validation to confirm antibody specificity. Western blotting should detect PLAUR at its expected molecular weight of 37 kDa . Pre-adsorption with recombinant PLAUR protein should eliminate specific binding. For more rigorous validation, immunoprecipitation followed by mass spectrometry analysis can confirm that the antibody captures the intended target.

Verify the expected subcellular localization pattern. Since PLAUR is primarily localized to the cell membrane, immunofluorescence or immunohistochemistry should demonstrate predominant membrane staining . Subcellular fractionation followed by Western blotting can biochemically confirm this localization pattern, with PLAUR enrichment in membrane fractions comparable to known membrane markers like Na+/K+-ATPase .

Cross-validate across detection methods when possible. Correlation between protein detection by antibody-based methods and mRNA expression can provide additional confidence in antibody specificity. Using multiple antibodies targeting different PLAUR epitopes and comparing their staining patterns can further validate specificity.

Finally, include appropriate controls in every experiment. Isotype controls should be included to identify potential non-specific binding. Depending on the application, appropriate positive controls (cells/tissues known to express PLAUR) and negative controls (PLAUR-negative samples) should be incorporated into the experimental design.

What expression patterns of PLAUR should researchers expect across different cell types and tissues?

PLAUR exhibits distinct expression patterns across diverse cell types and tissues, which researchers should consider when designing experiments and interpreting results. Understanding these expression patterns is crucial for selecting appropriate positive controls and interpreting experimental findings in the proper biological context.

In the context of cancer biology, PLAUR expression varies considerably across tumor types and subtypes. Aggressive breast cancer subtypes, particularly triple-negative breast cancer (TNBC), exhibit substantially elevated PLAUR expression compared to normal breast tissue or less aggressive cancer subtypes . This differential expression pattern has made PLAUR an attractive target for both diagnostic imaging and therapeutic intervention in aggressive cancers.

At the subcellular level, PLAUR is primarily localized to the cell membrane, consistent with its function as a cell surface receptor . This membrane localization has been confirmed through various techniques including immunofluorescence, electron microscopy, and biochemical fractionation of membrane proteins . When validating new PLAUR antibodies, researchers should expect to observe this characteristic membrane staining pattern in PLAUR-positive cells.

During experimental design, researchers should select appropriate positive and negative controls based on these established expression patterns. Myeloid lineage cells provide reliable positive controls for PLAUR expression, while PLAUR-knockout cells or tissues from PLAUR-knockout animals serve as definitive negative controls for antibody validation.

How can PLAUR antibodies be utilized to investigate PLAUR's role in HIV-1 restriction in myeloid cells?

PLAUR antibodies offer powerful tools for elucidating the mechanisms by which PLAUR restricts HIV-1 infection in myeloid lineage cells. A comprehensive investigation requires multiple complementary approaches to analyze PLAUR's expression, localization, and functional interactions during viral infection.

To characterize PLAUR expression in the context of HIV-1 infection, researchers can employ flow cytometry with anti-PLAUR antibodies to quantify surface expression on monocytes, macrophages, and dendritic cells from HIV-infected versus uninfected donors . This approach can reveal how infection alters PLAUR levels and correlate these changes with disease progression markers. Immunofluorescence microscopy using validated anti-PLAUR antibodies enables visualization of PLAUR redistribution during infection and potential colocalization with viral proteins .

For investigating PLAUR-mediated viral restriction mechanisms, functional blocking experiments using neutralizing anti-PLAUR antibodies can determine whether antibody-mediated inhibition of PLAUR function affects viral production. If PLAUR restricts HIV-1 release as suggested by the literature, blocking PLAUR function should enhance viral production . Complementary to this approach, researchers can use immunoprecipitation with anti-PLAUR antibodies to identify PLAUR-interacting proteins during HIV-1 infection, potentially revealing cofactors involved in restriction.

To examine direct interactions between PLAUR and HIV-1 components, advanced microscopy techniques are invaluable. Proximity ligation assays using antibodies against PLAUR and HIV-1 Gag can detect close associations between these proteins at the cell membrane . For higher resolution analysis, immunoelectron microscopy with gold-labeled PLAUR antibodies can visualize PLAUR localization relative to budding virions, providing direct evidence for PLAUR's proposed role in blocking virion release .

The interplay between uPA and PLAUR during HIV-1 infection represents another critical area for investigation. Flow cytometry measuring PLAUR levels after uPA treatment in HIV-infected cells, combined with viral production assays in the presence of uPA and anti-PLAUR antibodies, can elucidate how the uPA-PLAUR system modulates viral restriction .

What methodological considerations are important when using PLAUR antibodies for cancer imaging and therapy?

PLAUR antibodies have demonstrated significant potential for both cancer imaging and therapeutic applications, but their successful implementation requires careful methodological optimization. Researchers must consider multiple factors spanning from antibody selection to in vivo application protocols.

For imaging applications, antibody format selection significantly impacts performance. While full-length antibodies offer high specificity and binding affinity, their large size (150 kDa) can limit tumor penetration . Smaller formats such as F(ab')2 or Fab fragments may improve tumor penetration while reducing background signal in non-target organs. Antibody engineering approaches, including the development of recombinant human anti-PLAUR antibodies, have shown promise in preclinical studies for both imaging and therapeutic applications .

The choice of imaging modality and corresponding conjugation strategy is critical for successful PLAUR visualization. Near-infrared fluorescence imaging using fluorophore-conjugated anti-PLAUR antibodies allows for high-sensitivity detection with minimal tissue autofluorescence . For tomographic imaging with better tissue penetration, radiolabeling with isotopes such as 111In for single-photon emission computed tomography (SPECT) has proven effective for detecting PLAUR-positive tumors, including small disseminated lesions that may be missed by conventional imaging methods .

For therapeutic applications, antibodies can be utilized as unconjugated agents or as delivery vehicles for cytotoxic payloads. Antagonistic recombinant human anti-PLAUR antibodies have demonstrated efficacy as monotherapy in preclinical models, significantly decreasing tumor growth in triple-negative breast cancer xenografts . When conjugated to therapeutic radioisotopes such as 177Lu, these antibodies effectively reduced tumor burden in vivo, highlighting their potential for radioimmunotherapy applications .

Critical parameters requiring optimization include antibody dose, imaging timepoint, and detection thresholds. Too low a dose may result in insufficient signal, while excessive dosing can increase background and potentially saturate clearance mechanisms. Optimal imaging timepoints must balance sufficient tumor accumulation with adequate background clearance, typically 24-72 hours post-injection for full antibodies .

How does the uPA-PLAUR interaction affect experimental outcomes when using PLAUR antibodies?

The interaction between urokinase plasminogen activator (uPA) and its receptor PLAUR introduces important considerations for experimental design and interpretation when using PLAUR antibodies. This ligand-receptor interaction can significantly impact antibody binding, functional assays, and therapeutic outcomes.

The binding of uPA to PLAUR induces conformational changes in PLAUR that can alter epitope accessibility and antibody recognition . Certain antibodies may show reduced binding to PLAUR when the receptor is occupied by uPA, while others target epitopes unaffected by ligand binding. When designing experiments, researchers should consider whether their antibodies recognize free PLAUR, uPA-bound PLAUR, or both forms. Pre-incubation with uPA before antibody detection can help characterize epitope accessibility in the ligand-bound state.

In functional studies, the interaction between uPA and PLAUR has significant biological consequences. As demonstrated in HIV research, uPA can compromise PLAUR-mediated inhibition of HIV-1 production in macrophages and dendritic cells . When designing blocking experiments with anti-PLAUR antibodies, researchers should consider whether their antibodies prevent uPA binding. Comparison of antibodies that block versus permit uPA binding can help dissect the specific contributions of PLAUR's scaffolding functions versus its signaling activities.

In imaging applications, the endogenous uPA levels in target tissues may affect antibody binding and signal intensity. Tissues with high uPA expression might show reduced binding of antibodies targeting uPA-sensitive epitopes. This potential variable should be considered when interpreting imaging results, particularly when comparing different tissue types or pathological states with varying uPA expression levels.

What approaches can researchers use to study PLAUR's membrane localization using antibody-based techniques?

PLAUR's membrane localization is crucial for its biological functions, and multiple antibody-based approaches can effectively visualize and characterize this localization pattern. These techniques range from conventional microscopy to advanced biophysical methods.

Immunofluorescence microscopy using validated anti-PLAUR antibodies provides the most direct visualization of PLAUR's membrane localization. When performed on viable cells with antibodies targeting extracellular domains, this approach reveals a distinctive membrane staining pattern, as demonstrated in studies using both GFP-tagged and untagged PLAUR . For optimal results, researchers should use minimal fixation to preserve native membrane architecture while enabling antibody access. Comparing staining patterns with established membrane markers (like Na+/K+-ATPase) can confirm genuine membrane localization .

Super-resolution microscopy techniques offer enhanced visualization of PLAUR's membrane distribution. Structured illumination microscopy (SIM), stimulated emission depletion (STED), or single-molecule localization methods (PALM/STORM) can resolve PLAUR distribution within membrane microdomains with 20-50 nm resolution. These approaches require fluorophore-conjugated anti-PLAUR antibodies optimized for the specific super-resolution technique.

Biochemical verification of membrane localization can be achieved through subcellular fractionation followed by Western blotting with anti-PLAUR antibodies. This approach has successfully demonstrated PLAUR enrichment in membrane fractions comparable to established membrane markers . For quantitative assessment, researchers can perform surface biotinylation followed by streptavidin pulldown and anti-PLAUR immunoblotting to specifically measure the proportion of PLAUR at the cell surface versus intracellular compartments.

Electron microscopy with immunogold labeling provides the highest resolution visualization of PLAUR's precise membrane localization. This technique has been successfully employed to examine membrane-associated HIV-1 particles in relation to PLAUR, showing that PLAUR colocalizes with HIV-1 Gag protein at the cell membrane and blocks the release of HIV-1 progeny . Optimal protocols include fixation with 4% paraformaldehyde with 0.1% glutaraldehyde, embedding in hydrophilic resins, and immunogold labeling with anti-PLAUR antibodies followed by gold-conjugated secondary antibodies.

How can researchers optimize PLAUR antibody-based detection in complex tissue microenvironments?

Detecting PLAUR expression in complex tissue microenvironments presents unique challenges requiring specialized optimization strategies. The heterogeneous cellular composition, varied autofluorescence properties, and potential for non-specific interactions in tissues necessitate refined approaches beyond those used in cell culture systems.

Antigen retrieval optimization is critical for successful PLAUR detection in fixed tissues. Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) should be systematically compared to determine optimal conditions for specific anti-PLAUR antibodies. Since PLAUR is a membrane-anchored protein, excessive fixation can mask epitopes, so researchers should consider testing shortened fixation times or milder fixatives when preparing tissues .

Background reduction strategies are essential for achieving optimal signal-to-noise ratios. Tissue autofluorescence can be mitigated through chemical treatments (sodium borohydride, Sudan Black B) or spectral unmixing during image acquisition. For chromogenic detection methods, endogenous peroxidase blocking (3% H₂O₂) and avidin/biotin blocking (for biotin-based detection systems) should be incorporated. Additionally, optimization of blocking solutions (testing different concentrations of serum, BSA, or commercial blocking reagents) can significantly reduce non-specific binding .

Multiplexed detection approaches enable visualization of PLAUR in the context of specific cell types and microenvironmental features. Sequential multiplexed immunohistochemistry, multiplex immunofluorescence, or mass cytometry can simultaneously detect PLAUR along with lineage markers, functional proteins, and other microenvironmental components. These approaches are particularly valuable when studying heterogeneous tissues like tumors, where PLAUR expression may vary across different cell populations .

Signal amplification methods can enhance detection sensitivity in tissues with low PLAUR expression. Tyramide signal amplification, polymer-based detection systems, or quantum dot-based approaches can significantly increase detection sensitivity without compromising specificity. These methods are particularly valuable when examining early-stage pathological changes or cell types with naturally low PLAUR expression levels.

Validation through complementary techniques strengthens the reliability of PLAUR detection in tissues. Correlation of immunohistochemistry findings with RNA in situ hybridization or analysis of adjacent sections with different PLAUR antibodies targeting distinct epitopes provides stronger evidence for genuine PLAUR expression. Additionally, comparison with known PLAUR expression patterns in positive control tissues (e.g., myeloid-rich tissues) can serve as valuable reference points.

What are the emerging therapeutic applications of PLAUR antibodies in cancer research?

PLAUR antibodies are emerging as promising agents for cancer diagnosis and therapy, with several innovative approaches under investigation. Their specificity for a receptor overexpressed in aggressive cancer subtypes makes them attractive candidates for targeted interventions with potentially reduced off-target effects.

Antagonistic recombinant human anti-PLAUR antibodies have demonstrated significant efficacy as monotherapy in preclinical models. In triple-negative breast cancer xenografts, treatment with these antibodies resulted in a substantial decrease in tumor growth, providing proof-of-concept for direct therapeutic targeting of PLAUR . These findings are particularly significant considering that triple-negative breast cancer lacks established targeted therapies, representing an area of significant unmet clinical need.

Radioimmunotherapy using anti-PLAUR antibodies conjugated to therapeutic radioisotopes represents another promising approach. Studies using 177Lu-conjugated anti-PLAUR antibodies have shown effectiveness in reducing tumor burden in vivo . This strategy leverages the specificity of antibody targeting to deliver localized radiation therapy to tumor cells while potentially minimizing exposure to normal tissues. The radioisotope 177Lu is particularly suitable for this application due to its moderate tissue penetration range and half-life of 6.7 days, which aligns well with antibody pharmacokinetics.

Diagnostic imaging applications also show considerable promise. PLAUR antibody-based imaging probes have successfully detected small disseminated lesions in tumor metastasis models, complementing conventional 18F-fluorodeoxyglucose positron emission tomography by identifying non-glucose-avid metastatic lesions that might otherwise be missed . This capability could significantly improve cancer staging and treatment planning by providing more comprehensive detection of metastatic disease.

Future directions include the development of bispecific antibodies that simultaneously target PLAUR and engage immune effectors, antibody-drug conjugates delivering potent cytotoxic agents to PLAUR-expressing cells, and combinations with other therapeutic modalities such as immune checkpoint inhibitors. The potential for using PLAUR expression as a predictive biomarker for patient stratification also represents an important area for further investigation.

How can PLAUR antibodies contribute to understanding and treating infectious diseases?

PLAUR antibodies serve as valuable tools for investigating host-pathogen interactions, particularly in the context of viral infections where PLAUR plays significant regulatory roles. The discovery of PLAUR as an antiviral factor opens new avenues for both basic research and therapeutic development.

In HIV-1 infection, PLAUR antibodies have revealed a novel restriction mechanism in myeloid lineage cells. PLAUR functions as an antiviral factor in macrophages and dendritic cells by blocking the release of HIV-1 progeny virions from the cell membrane . This finding has significant implications for understanding viral pathogenesis, as macrophages and dendritic cells are less permissive to HIV-1 infection compared to stimulated CD4+ T lymphocytes, particularly during early infection phases. PLAUR antibodies enable visualization of this restriction mechanism through techniques like immunoelectron microscopy, which demonstrates PLAUR colocalization with HIV-1 Gag at the cell membrane .

The interaction between PLAUR and its ligand uPA introduces additional complexity to viral regulation. Using anti-PLAUR antibodies, researchers have determined that uPA compromises PLAUR-mediated inhibition, slightly enhancing HIV-1 production in primary macrophages and dendritic cells . This finding suggests that the uPA-PLAUR system represents a potential therapeutic target for modulating HIV-1 infection in myeloid cells.

Expression analysis using PLAUR antibodies has revealed altered expression patterns in infectious contexts. While granulocytes and monocytes normally express high levels of PLAUR, granulocytes from HIV-infected individuals show reduced PLAUR expression that correlates with CD4+ T lymphocyte counts . This correlation suggests potential diagnostic applications for monitoring disease progression.

Future therapeutic strategies might leverage PLAUR's antiviral properties by enhancing its expression or activity in susceptible cells, or by developing small molecules that mimic PLAUR's viral restriction mechanism. PLAUR antibodies will be instrumental in screening and validating such approaches. Additionally, the role of PLAUR in other viral infections remains largely unexplored, representing an important area for future investigation using PLAUR antibodies.

What methodological advances are improving the development and application of PLAUR antibodies?

Methodological advances across multiple disciplines are enhancing both the development and application of PLAUR antibodies, expanding their utility in research and clinical contexts. These innovations span antibody engineering, detection technologies, and analytical approaches.

Recombinant antibody technology has revolutionized PLAUR antibody development. Human recombinant anti-PLAUR antibodies have demonstrated excellent specificity and efficacy in preclinical studies for both diagnostic imaging and therapeutic applications . This approach eliminates batch-to-batch variation associated with traditional polyclonal antibodies and reduces immunogenicity concerns in therapeutic applications. Additionally, antibody engineering enables the development of optimized formats, including domain-specific antibodies, bispecific constructs, and antibody fragments with improved tissue penetration.

Advanced conjugation chemistries are expanding the functional repertoire of PLAUR antibodies. Site-specific conjugation methods preserve antibody function by attaching payloads (fluorophores, radioisotopes, or drugs) at defined positions away from the antigen-binding region. For radioimmunoconjugates, chelator development has improved radioisotope stability and pharmacokinetics, enhancing both imaging and therapeutic applications . Similarly, advances in fluorophore technology, particularly in the near-infrared range, have improved signal-to-background ratios for in vivo imaging applications.

Multiplexed detection systems enable simultaneous visualization of PLAUR alongside multiple other markers. Multiplexed immunofluorescence, mass cytometry (CyTOF), and digital spatial profiling technologies permit comprehensive analysis of PLAUR expression in relation to cell types, activation states, and microenvironmental features. These approaches are particularly valuable for understanding PLAUR's roles in complex tissues like tumors or infected tissues with heterogeneous cellular compositions.

Artificial intelligence and computational analysis are transforming image-based PLAUR detection. Machine learning algorithms can enhance signal detection, reduce artifacts, and extract quantitative data from PLAUR antibody-based imaging. In diagnostic applications, AI-assisted image analysis improves the sensitivity and reproducibility of PLAUR detection, potentially enabling more accurate patient stratification based on PLAUR expression patterns.

Improved validation methodologies ensure antibody specificity and reproducibility. Standardized validation pipelines incorporating genetic controls (CRISPR knockout), orthogonal detection methods (RNA-sequencing, mass spectrometry), and multi-site reproducibility testing enhance confidence in antibody performance across different applications and experimental systems.